IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder typically associated with tumefactive (puffy) swelling of glandular tissues, with fibrosis and infiltration of affected organs by polyclonal lymphocytes, IgG4+ plasma cells, and eosinophils. About 70% of patients also have elevated serum IgG4 levels. Nearly any organ system can be involved, but like the non-caseating granulomas of sarcoidosis, the histological findings are very similar throughout diverse tissues: storiform (matted and irregularly whorled) fibrosis, oblitative phlebitis, lymphoplasmacytic infiltrate, and eosinophilia. IgG4-RD has been shown to be the underlying cause of numerous diseases which were previously thought unrelated, such as autoimmune pancreatitis,1 Mikulicz’ disease, and multifocal fibrosclerosis. Table 1 lists other manifestations.

This concise review focuses on three questions:

- When should I suspect IgG4-RD?
- How do I approach diagnosis of IgG4-RD?
- How do I treat IgG4-RD?

A number of detailed reviews are recommended for further reading.2-4

When should I suspect IgG4-RD?

Patients typically present with a subacute course, many with chronic unrecognized disease manifestations. The most common disease features are autoimmune pancreatitis, sialoadenitis, lacrimal gland involvement, and retroperitoneal fibrosis. One third of patients have associated atopy, asthma, and eosinophilia.5 This case illustrates classic manifestations and the likelihood of IgG4-RD is extremely high. Her features of eosinophilia, polyclonal hypergammaglobulinemia, increased IgG, modestly elevated CRP, and negative or weakly positive autoantibodies are also consistent with IgG4-RD.

How do I approach the diagnosis of IgG4-RD?

When a case is suspected, the diagnostic tests in Table 2 should be considered. Most important is pathologic review of the tissue specimens. In many cases, archived tissue samples are available; if not, then the most affected organ with lowest risk of morbidity from biopsy should be sampled. Excisional biopsy is preferred over a core biopsy. Minor salivary gland biopsy can be considered in those...
patients where a biopsy of other affected organs (such as retroperitoneal fibrosis) requires laparotomy or is otherwise too high-risk. If histologic findings are suggestive of IgG4-RD, immunostaining for IgG and IgG4 should be done (Figure 1). The International Consensus Criteria are applied, wherein for most tissues, an IgG4 count > 50 hpf-100/hpf, and IgG4/IgG ratio > 40% with appropriate histologic findings, is considered diagnostic. Increased IgG4 positive plasma cells are not in themselves specific, and can be found in many “mimickers” of IgG4-RD such as Sjögren’s syndrome, lymphoma, other malignancies, vasculitis, and Castleman’s disease. Classic autoimmune pancreatitis with typical radiologic findings is the one situation where histologic confirmation of diagnosis may not be required.

The patient’s excisional salivary gland biopsy from 1996 was reviewed and confirmed “a prominent lymphoplasmacytic infiltrate associated with prominent fibrosis. The number of IgG4-positive plasma cells is increased, and there are multiple high power fields that contain more than 100 positive cells. The IgG4:IgG ratio is greater than 40%.” Bloodwork revealed markedly elevated serum IgG4 of 25.7 g/L with other subclasses normal or slightly elevated (normal < 1.25 g/L). The pathology and lab tests confirm the diagnosis of IgG4-RD.

How do I treat IgG4-related disease?
Treatment is aimed at reducing symptoms, preventing further organ damage, and stabilizing fibrosis (which is typically not reversible). Initial treatment is usually with prednisone 1 mg/kg, with an 80% response rate reported. The main toxicity is new or worsening diabetes, since many of these patients have pancreatic impairment to begin with. B-cell depletion with rituximab (1 gram IV Q2 weeks x 2 doses) is very effective, through ablation of the short-lived plasma cells producing a polyclonal hypergammaglobulinemia (elevation in IgG4, other IgG subclasses, and other Ig’s, sometimes to the point of hyperviscosity syndrome). The main toxicity is new or worsening diabetes, since many of these patients have pancreatic impairment to begin with. B-cell depletion with rituximab (1 gram IV Q2 weeks x 2 doses) is very effective, through ablation of the short-lived plasma cells producing a polyclonal hypergammaglobulinemia (elevation in IgG4, other IgG subclasses, and other Ig’s, sometimes to the point of hyperviscosity syndrome). The main toxicity is new or worsening diabetes, since many of these patients have pancreatic impairment to begin with. B-cell depletion with rituximab (1 gram IV Q2 weeks x 2 doses) is very effective, through ablation of the short-lived plasma cells producing a polyclonal hypergammaglobulinemia (elevation in IgG4, other IgG subclasses, and other Ig’s, sometimes to the point of hyperviscosity syndrome).
IgG4. Duration of remission is variable, however, and many patients require re-treatment. The standardized IgG4-RD Responder Index can be used to monitor patients. Patients with markedly elevated serum IgG4 at baseline have a convenient and non-invasive means of monitoring, although relapses have been known to occur even with normal serum IgG4. Plasmablast flow cytometry is under investigation as a more sensitive marker of disease activity.

This patient had an excellent response to prednisone 1 mg/kg x 4 weeks followed by a slow taper. Because of the extent of her disease burden and risk of progression to end stage renal disease, she was also given rituximab 1 gram IV x 3 doses. She remains in remission, with normal eosinophils, serum IgG and IgG4, and ACR on maintenance prednisone 5 mg/day.

References & Suggested Readings
For further information, please contact lchen2@bccancer.bc.ca.

Table 2

<table>
<thead>
<tr>
<th>Tests</th>
<th>Typical Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>CBC/differential/blood film</td>
<td>Eosinophilia</td>
</tr>
<tr>
<td>CRP (also IL-6, other markers of systemic inflammation)</td>
<td>Mild-moderate elevation</td>
</tr>
<tr>
<td>IgG subclasses</td>
<td>Mild elevation in IgG4 nonspecific, and 30% of IgG4-RD patients have normal serum IgG4 levels. Markedly elevated serum IgG4 is helpful both for diagnosis and as a disease marker.</td>
</tr>
<tr>
<td>Immunoglobulins (IgG, IgA, IgM, IgE), serum and urine protein, electrophoresis (SPEP, UPEP)</td>
<td>Other immunoglobulins may also be elevated. SPEP and UPEP are important to rule out monoclonal proteins.</td>
</tr>
<tr>
<td>Autoantibodies</td>
<td>May be weakly positive</td>
</tr>
<tr>
<td>Other markers of end organ damage: creatinine, liver enzymes, lipase, urinalysis, urine albumin/creatinine ratio</td>
<td>Variable; many patients may have subclinical involvement of organs other than the presenting problem</td>
</tr>
<tr>
<td>CT or MRI of affected area. Some patients may benefit from a “staging CT” from head (sinuses) to pelvis.</td>
<td>Pancreas and kidneys become diffusely enlarged. Ductal organs such as bile duct, bronchus, show diffuse “pipe-stem” wall thickening.</td>
</tr>
<tr>
<td>Archived specimens</td>
<td>As long as tissue blocks are still available, the pathologist should be able to examine the histology and then order immunostaining for IgG and IgG4 if typical features are present.</td>
</tr>
<tr>
<td>New biopsy</td>
<td>Excisional is preferable to core biopsy when possible.</td>
</tr>
<tr>
<td>Bone marrow/lymph node</td>
<td>These tissues are unusual in that fibrosis and obliterative phlebitis are typically not seen, and thus biopsy of other tissues may be required for definitive diagnosis.</td>
</tr>
</tbody>
</table>

Luke Chen, MD, FRCP, MMed
Clinical Assistant Professor,
Division of Hematology,
University of British Columbia
Hematologist,
Vancouver General Hospital
Vancouver, British Columbia